Recovery of Drug Delivery Nanoparticles from Human Plasma Using an Electrokinetic Platform Technology.

The effect of complex biological fluids on the surface and structure of nanoparticles is a rapidly expanding field of study. One of the challenges holding back this research is the difficulty of recovering therapeutic nanoparticles from biological samples due to their small size, low density, and stealth surface coatings. Here, the first demonstration of the recovery and analysis of drug delivery nanoparticles from undiluted human plasma samples through the use of a new electrokinetic platform technology is presented. The particles are recovered from plasma through a dielectrophoresis separation force that is created by innate differences in the dielectric properties between the unaltered nanoparticles and the surrounding plasma. It is shown that this can be applied to a wide range of drug delivery nanoparticles of different morphologies and materials, including low-density nanoliposomes. These recovered particles can then be analyzed using different methods including scanning electron microscopy to monitor surface and structural changes that result from plasma exposure. This new recovery technique can be broadly applied to the recovery of nanoparticles from high conductance fluids in a wide range of applications.

[1]  Albert Duschl,et al.  Hardening of the nanoparticle-protein corona in metal (Au, Ag) and oxide (Fe3O4, CoO, and CeO2) nanoparticles. , 2011, Small.

[2]  Michael J Heller,et al.  Dielectrophoretic isolation of DNA and nanoparticles from blood , 2012, Electrophoresis.

[3]  Stefan Tenzer,et al.  Rapid formation of plasma protein corona critically affects nanoparticle pathophysiology. , 2013, Nature nanotechnology.

[4]  Michael J Heller,et al.  Rapid electrokinetic isolation of cancer-related circulating cell-free DNA directly from blood. , 2014, Clinical chemistry.

[5]  K. Caldwell,et al.  Surface modification of nanoparticles by PEO/PPO block copolymers to minimize interactions with blood components and prolong blood circulation in rats. , 1993, Biomaterials.

[6]  Rajesh Singh,et al.  Nanoparticle-based targeted drug delivery. , 2009, Experimental and molecular pathology.

[7]  Michael J Heller,et al.  Low level epifluorescent detection of nanoparticles and DNA on dielectrophoretic microarrays , 2014, Journal of biophotonics.

[8]  Parag Aggarwal,et al.  Nanoparticle interaction with plasma proteins as it relates to particle biodistribution, biocompatibility and therapeutic efficacy. , 2009, Advanced drug delivery reviews.

[9]  Shaoyi Jiang,et al.  Zwitterionic polymers exhibiting high resistance to nonspecific protein adsorption from human serum and plasma. , 2008, Biomacromolecules.

[10]  Samir Mitragotri,et al.  Factors that control the circulation time of nanoparticles in blood: challenges, solutions and future prospects. , 2010, Current pharmaceutical design.

[11]  Iseult Lynch,et al.  What the cell "sees" in bionanoscience. , 2010, Journal of the American Chemical Society.

[12]  Sadik C Esener,et al.  Interaction of Nanoparticles at the DEP Microelectrode Interface under High Conductance Conditions. , 2009, Electrochemistry communications.

[13]  R. Müller,et al.  Nanoparticles with decreasing surface hydrophobicities: influence on plasma protein adsorption. , 2000, International journal of pharmaceutics.

[14]  Marco P Monopoli,et al.  Biomolecular coronas provide the biological identity of nanosized materials. , 2012, Nature nanotechnology.

[15]  Sadik C Esener,et al.  Alternating current electrokinetic separation and detection of DNA nanoparticles in high‐conductance solutions , 2008, Electrophoresis.

[16]  Sara Linse,et al.  Understanding the nanoparticle–protein corona using methods to quantify exchange rates and affinities of proteins for nanoparticles , 2007, Proceedings of the National Academy of Sciences.

[17]  W. Semmler,et al.  Determination of Plasma Protein Adsorption on Magnetic Iron Oxides: Sample Preparation , 1997, Pharmaceutical Research.

[18]  Iseult Lynch,et al.  The evolution of the protein corona around nanoparticles: a test study. , 2011, ACS nano.

[19]  R. Müller,et al.  'Stealth' corona-core nanoparticles surface modified by polyethylene glycol (PEG): influences of the corona (PEG chain length and surface density) and of the core composition on phagocytic uptake and plasma protein adsorption. , 2000, Colloids and surfaces. B, Biointerfaces.

[20]  Michael J. Heller,et al.  Dielectrophoretic isolation and detection of cancer‐related circulating cell‐free DNA biomarkers from blood and plasma , 2014, Electrophoresis.

[21]  Kiselev Ma,et al.  Size of a human serum albumin molecule in solution , 2001 .

[22]  Kazuo Maruyama,et al.  Amphipathic polyethyleneglycols effectively prolong the circulation time of liposomes , 1990, FEBS letters.

[23]  H. Morgan,et al.  Ac electrokinetics: a review of forces in microelectrode structures , 1998 .

[24]  Y Li,et al.  PEGylated PLGA nanoparticles as protein carriers: synthesis, preparation and biodistribution in rats. , 2001, Journal of controlled release : official journal of the Controlled Release Society.

[25]  F. Zihnioglu,et al.  Comparison of five methods for determination of total plasma protein concentration. , 2007, Journal of biochemical and biophysical methods.

[26]  Lei Zhang,et al.  Functionalizable and ultra stable nanoparticles coated with zwitterionic poly(carboxybetaine) in undiluted blood serum. , 2009, Biomaterials.

[27]  Joseph M. DeSimone,et al.  Strategies in the design of nanoparticles for therapeutic applications , 2010, Nature Reviews Drug Discovery.

[28]  Michael J Heller,et al.  Dielectrophoretic isolation and detection of cfc‐DNA nanoparticulate biomarkers and virus from blood , 2013, Electrophoresis.